Sanofi plans to release a new Pompe's disease treatment in Korea. It is known that Nexviazyme, which was approved by the U.S. FDA in August, recently applied for permission from the MFDS.

According to the MFDS on the 1st, Sanofi Aventis Korea submitted a report on the results of clinical trials by Nexviazyme (Avalglucosidase alfa-ngpt) and applied for permission.

This drug is a Pompe's disase treatment. Pompe's disease is a genetic disorder in which respiratory failure and myocardial disease appear due to muscle strength loss and muscle atrophy. It is a rare disease that is reported to be about one person per 40,000 people worldwide, and it is known that there are about 1,300 patients in